Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Array BioPharma to Cut 20 Percent of its Jobs

By Pharmaceutical Processing | August 7, 2013

Array BioPharma Inc. said Wednesday it will eliminate around 50 jobs, or 20 percent of its staff positions, after Amgen Inc. ended a partnership with Array on diabetes drugs.

Array said it was informed of Amgen’s decision this week. It will regain the rights to the products the companies were developing together, including one drug in mid-stage clinical testing. The Boulder, Colo., company said it will have around 200 employees after the cuts are made.

Shares of Array fell 25 cents, or 4 percent, to $6.30 in aftermarket trading.

Amgen and Array announced a collaboration on type 2 diabetes drugs in December 2009. Amgen paid Array $60 million upfront and also agreed to fund some full-time Array employees as part of a two-year research collaboration.

The most-advanced drug the companies were developing is called ARRY-403 or AMG-151. It is designed to help the body produce more insulin. Array said Amgen recently finished a mid-stage trial and it will share results from that study soon.

The company also reported its fiscal fourth quarter results on Wednesday. Array said it lost $17.6 million, or 15 cents per share. A year ago it took a loss of $8 million, or 9 cents per share. If one-time items are excluded the company said its loss decreased to 6 cents per share from 9 cents per share. Revenue grew 23 percent, to $25.4 million from $20.7 million after Array received a license payment from Oncothyreon Inc. and a milestone payment from Novartis AG.

Analysts were expecting an adjusted loss of 13 cents per share and $16.3 million in revenue, according to FactSet. The company’s fiscal fourth quarter ended June 30.

In the fourth quarter the company took a one-time charge of $11.2 million charge for early repayment of debt.

Array said it lost $61.9 million, or 57 cents per share, in fiscal 2013 after losing $23.6 million, or 33 cents per share, in fiscal 2012. Revenue fell 18 percent, to $69.6 million from $85.1 million.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE